Urologische Klinik

Megaprepuce: presentation of a modified surgical technique with excellent cosmetic and functional results (2019) Hirsch K, Schwaiger B, Kraske S, Wullich B Journal article Erratum zu: Therapiesituation beim metastasierten kastrationsnaiven Prostatakarzinom (mCNPC) und die Auswirkungen im klinischen Alltag (Der Urologe, (2019), 10.1007/s00120-019-0925-2) (2019) Wülfing C, Bögemann M, Goebell P, Hammerer P, Machtens S, Pfister D, Schwentner C, et al. Journal article, Erratum Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review (2019) Kunath F, Goebell P, Wullich B, Sikic D, Kahlmeyer A Journal article, Review article Molecular tumor board—renal cell carcinoma Molekulares Tumorboard – Nierenzellkarzinom (2019) Grünwald V, Doehn C, Goebell P Journal article, Review article Association Between Exstrophy-epispadias Complex And Congenital Anomalies: A German Multicenter Study (2019) Ebert AK, Zwink N, Jenetzky E, Stein R, Boemers TM, Lacher M, Fortmann C, et al. Journal article Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine Therapiesituation beim metastasierten kastrationsnaiven Prostatakarzinom (mCNPC) und die Auswirkungen im klinischen Alltag (2019) Wülfing C, Bögemann M, Goebell P, Hammerer P, Machtens S, Pfister D, Schwentner C, et al. Journal article, Review article sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro (2019) Tsaur I, Hüsch T, Jüngel E, Schneider F, Schneider M, Haferkamp A, Thomas C, et al. Journal article New horizons in bladder cancer research (2019) Boormans JL, Zwarthoff EC, Black PC, Goebell P, Kamat AM, Nawroth R, Seiler R, et al. Journal article, Review article Editorial: Basic research in bladder cancer – refining the tools. 3rd IBCN seminars series1 (2019) Black PC, Goebell P, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ Journal article Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab (2019) Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiss CA, Wirtz RM, Wach S, et al. Journal article